LAB282 is an exciting £13m public private partnership between the University, Oxford Sciences Innovation, and the international drug discovery company Evotec AG, to accelerate drug discovery in Oxford. There is currently a lack of funding to help translate basic research in disease-related biological pathways into focused drug discovery programmes. LAB282 seeks to address this unmet need, to stimulate the formation of new projects and companies to develop ground-breaking therapies, and ultimately to generate patient benefit. LAB282 projects will be sourced from across the research activities in the University of Oxford, from any disease area and will include all therapeutic modalities. Successful applicants will partner with Evotec to gain access to their industry leading drug discovery services through an award based scheme. This talk will detail the LAB282 initiative and how to apply.